Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1981-8-10
pubmed:abstractText
Moxalactam, a new beta-lactam antibiotic with a wide in vitro spectrum of activity, was compared with cefazolin after intravenous and intramuscular administration of 1.0 g in a double-blind crossover design in 21 adult male subjects with normal renal function. Serum samples were obtained at 0.5, 1, 2, 3, 4, 6, 8, and 12 h, and urine was collected at 0 to 2, 2 to 4, 4 to 6, 6 to 8, and 8 to 12 h after dosing. Intravenous kinetics were described by a linear two-compartment model. For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin. Intramuscular kinetics were similar and were well described by a single-compartment model. Urinary recovery was essentially identical for both drugs: 55 to 75% in 8 h. Consistent departures from the two-compartment model for moxalactam (not noted for cefazolin) suggested enterohepatic recirculation of moxalactam. Both drugs were well tolerated, and no adverse reactions were noted.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-1107514, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-314774, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-4744015, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-4790584, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-507785, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-507788, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-518080, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-533267, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-560731, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-6247966, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-6247970, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-6249195, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-6446240, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-6446259, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-6447473, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-6448576, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-836010, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-842999, http://linkedlifedata.com/resource/pubmed/commentcorrection/6454387-942138
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
613-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1981
pubmed:articleTitle
Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Controlled Clinical Trial